Veradigm Announces Strategic Investment in Holmusk

Veradigm Inc.Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.

Holmusk will leverage this investment to continue its rapid expansion of its flagship offering, the NeuroBlu Database - a leading source of real-world clinical data for the behavioral health industry.

Now that the financing has been completed, Veradigm and Holmusk intend to enter into a data partnership to bring cohorts of behavioral health and related de-identified patient data from Veradigm to the NeuroBlu Database, significantly adding to Holmusk’s real-world clinical data asset.

"Mental and behavioral health is a serious global health problem that has only increased during and post the COVID-19 pandemic," said Rick Poulton, Veradigm Chief Executive Officer. "Holmusk has proven expertise to create the evidence needed to improve mental health. We are proud to equip the company with the resources needed to advance this important work."

"This investment will enable our team to continue its work in curating and enhancing data as we plan to build the world's largest platform for behavioral health data," said Nawal Roy, Holmusk Founder and CEO. "We remain laser-focused on this mission because we know that quality data leads to improved evidence, which leads to better health outcomes."

"We feel fortunate to form a partnership with Veradigm, a company that shares our vision for the transformative power that data can have in health care," said Michael Weintraub, Chair of the Holmusk Board. "Working collaboratively will help us to deepen our investment in the behavioral health space and make a broader impact."

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

About Holmusk

Holmusk is on a mission to harness real-world data to transform both research and care for behavioral health. Combining the leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk is headquartered in New York and Singapore, with three additional offices around the world.

Most Popular Now

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...

North West Anglia Works with Clinisys to…

North West Anglia NHS Foundation Trust has replaced two, legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...